← Leaderboards
Waldemar Debinski
Wake Forest University Health Sciences
$13,953,944
Attributed
$14,835,977
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,813,183 · 11
By mechanism
R01$11,853,018 · 5
P01$11,695,539 · 4
P30$237,626 · 1
R13$27,000 · 1
Top collaborators
- John Henry Rossmeisl3 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- John Henry Rossmeisl$2,426,879
- Steven A Akman$2,428,085
Others in their field
Top investigators on “Glioblastoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$50,454,235
- John H Sampson · Duke University$34,869,540
- Walter John Curran · Thomas Jefferson University$27,327,059
- Jann N Sarkaria · Mayo Clinic Coll Of Medicine, Rochester$23,947,143
- Jeremy N Rich · University Of Pittsburgh At Pittsburgh$21,935,828
- Maciej S Lesniak · Northwestern University$18,837,339
Research focus
GlioblastomaTumorCellsPharmaceutical PreparationsNeoplastic CellGliomaBrain NeoplasmsBaseBrainMolecularCytotoxinInterleukin-13RecurrenceReceptorMolecular TargetDrug Delivery SystemsLigandsDrug CandidateCanis FamiliarisPrimary Brain NeoplasmsPlaySiteBacterial ToxinsMonitor
Grant awards (64)
Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment$603,422
R01 · FY2025 · CA · contact PI
Multi-receptor Targeting of Glioblastoma$601,671
R01 · FY2024 · CA · contact PI
Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment$565,969
R01 · FY2024 · CA · contact PI
Multi-receptor Targeting of Glioblastoma$615,701
R01 · FY2023 · CA · contact PI
Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment$594,675
R01 · FY2023 · CA · contact PI
Multi-receptor Targeting of Glioblastoma$610,326
R01 · FY2022 · CA · contact PI
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma$1,827,419
P01 · FY2021 · CA · contact PI
Multi-receptor Targeting of Glioblastoma$642,795
R01 · FY2021 · CA · contact PI
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM$399,814
P01 · FY2021 · CA · contact PI
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM$141,793
P01 · FY2021 · CA · contact PI
Rapid Electrical Impedance Spectroscopy for Detection of High-Frequency Irreversible Electroporation Ablation Growth in a Rodent Glioma Model$141,793
P01 · FY2021 · CA · contact PI
Sub-component for Institution # 16-01848 Core 1 - Administrative$125,491
P01 · FY2021 · CA · contact PI
Neuro-Oncology Program$38,066
P30 · FY2021 · CA · contact PI
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma$1,671,109
P01 · FY2020 · CA · contact PI
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM$370,097
P01 · FY2020 · CA · contact PI
Sub-component for Institution # 16-01848 Core 1 - Administrative$90,965
P01 · FY2020 · CA · contact PI
Neuro-Oncology Program$37,850
P30 · FY2020 · CA · contact PI
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma$1,848,644
P01 · FY2019 · CA · contact PI
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM$411,108
P01 · FY2019 · CA · contact PI
High-Grade Astrocytoma-Specific Molecular Targeting$288,259
R01 · FY2019 · CA · contact PI
Sub-component for Institution # 16-01848 Core 1 - Administrative$118,670
P01 · FY2019 · CA · contact PI
Neuro-Oncology Program$96,814
P30 · FY2019 · CA · contact PI
Neuro-Oncology Program$29,409
P30 · FY2019 · CA · contact PI
Neuro-Oncology Program$14,689
P30 · FY2019 · CA · contact PI
Neuro-Oncology Program$11,763
P30 · FY2019 · CA · contact PI
Neuro-Oncology Program$5,639
P30 · FY2019 · CA · contact PI
Neuro-Oncology Program$3,396
P30 · FY2019 · CA · contact PI
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma$1,694,917
P01 · FY2018 · CA · contact PI
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM$399,165
P01 · FY2018 · CA · contact PI
High-Grade Astrocytoma-Specific Molecular Targeting$297,157
R01 · FY2018 · CA · contact PI
Sub-component for Institution # 16-01848 Core 1 - Administrative$125,518
P01 · FY2018 · CA · contact PI
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma$1,793,324
P01 · FY2017 · CA · contact PI
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM$406,708
P01 · FY2017 · CA · contact PI
High-Grade Astrocytoma-Specific Molecular Targeting$297,089
R01 · FY2017 · CA · contact PI
Sub-component for Institution # 16-01848 Core 1 - Administrative$129,004
P01 · FY2017 · CA · contact PI
High-Grade Astrocytoma-Specific Molecular Targeting$297,189
R01 · FY2016 · CA · contact PI
High-Grade Astrocytoma-Specific Molecular Targeting$310,984
R01 · FY2015 · CA · contact PI
Molecular Combinatorial Therapy of Glioblastoma Multiforme$290,398
R01 · FY2014 · CA · contact PI
High-Grade Astrocytoma-specific Molecular Targeting$237,999
R01 · FY2014 · CA · contact PI
Molecular Combinatorial Therapy of Glioblastoma Multiforme$281,376
R01 · FY2013 · CA · contact PI
High-Grade Astrocytoma-specific Molecular Targeting$230,637
R01 · FY2013 · CA · contact PI
Molecular Combinatorial Therapy of Glioblastoma Multiforme$301,034
R01 · FY2012 · CA · contact PI
High-Grade Astrocytoma-specific Molecular Targeting$245,359
R01 · FY2012 · CA · contact PI
Molecular Combinatorial Therapy of Glioblastoma Multiforme$309,154
R01 · FY2011 · CA · contact PI
High-Grade Astrocytoma-specific Molecular Targeting$245,359
R01 · FY2011 · CA · contact PI
Molecular Combinatorial Therapy of Glioblastoma Multiforme$307,100
R01 · FY2010 · CA · contact PI
High-Grade Astrocytoma-specific Molecular Targeting$252,947
R01 · FY2010 · CA · contact PI
Molecular Requirements for Recombinant Cytotoxins Efficacy$243,842
R01 · FY2010 · CA · contact PI
Ephrins and Cancer$9,000
R13 · FY2010 · CA · contact PI
Molecular Requirements for Recombinant Cytotoxins Efficacy$243,842
R01 · FY2009 · CA · contact PI
High-Grade Astrocytoma-specific Molecular Targeting$238,112
R01 · FY2009 · CA · contact PI
Ephrins and Cancer$9,000
R13 · FY2009 · CA · contact PI
Molecular Requirements for Recombinant Cytotoxins Efficacy$243,842
R01 · FY2008 · CA · contact PI
High-Grade Astrocytoma-specific Molecular Targeting$238,112
R01 · FY2008 · CA · contact PI
Molecular Requirements for Recombinant Cytotoxins Efficacy$243,842
R01 · FY2007 · CA · contact PI
High-Grade Astrocytoma-specific Molecular Targeting$238,112
R01 · FY2007 · CA · contact PI
Molecular Requirements for Recombinant Cytotoxins Efficacy$251,125
R01 · FY2006 · CA · contact PI
High-Grade Astrocytoma-specific Molecular Targeting$245,224
R01 · FY2006 · CA · contact PI
Ephrins and Cancer$9,000
R13 · FY2006 · CA · contact PI
High-Grade Astrocytoma-specific Molecular Targeting$251,125
R01 · FY2005 · CA
High Grade Astrocytoma Specific Molecular Targeting$251,344
R01 · FY2004 · CA
High Grade Astrocytoma Specific Molecular Targeting$245,875
R01 · FY2003 · CA
High Grade Astrocytoma Specific Molecular Targeting$245,875
R01 · FY2002 · CA
TUMOR SPECIFIC TARGET FOR THERAPEUTIC DELIVERIES$246,146
R01 · FY2000 · CA